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Purpose—We investigated the diagnostic and clinical performance of exome sequencing (ES) in 
fetuses with sonographic abnormalities with normal karyotype, microarray and, in some cases, 
normal gene specific sequencing.
Methods—ES was performed from DNA of 15 anomalous fetuses and from peripheral blood 
from their parents. Parents provided consent for the return of diagnostic results in the fetus, 
medically actionable findings in the parents, and identification as carrier couple for significant 
autosomal recessive conditions. We assessed perceptions and understanding of ES with mixed-
methods in 15 mother-father dyads.
Results—In 7 (47%) of 15 fetuses, ES provided a diagnosis or possible diagnosis with 
identification of variants in the following genes: COL1A1, MUSK, KCTD1, RTTN, TMEM67, 
PIEZO1; and DYNC2H1. One additional case revealed a de novo nonsense mutation in a novel 
candidate gene (MAP4K4). The perceived likelihood that ES would explain the results (5.2/10) 
was higher than the approximately 30% diagnostic yield discussed in pre-test counseling.
Conclusions—ES has diagnostic utility in a highly select population of fetuses where a genetic 
diagnosis was highly suspected. Challenges related to genetics literacy, and variant interpretation 
must be addressed by highly tailored pre- and post-test genetic counseling.
Keywords
prenatal; diagnosis; exome; ethics; counseling
INTRODUCTION
Congenital anomalies affect 2–4% of all infants and are responsible for 20% of perinatal 
deaths.1 Currently, prenatal diagnosis begins with a positive serum or cell free DNA screen 
for aneuploidy. This is followed by targeted anatomical survey and diagnostic tests such as 
chorionic villus sampling or amniocentesis. Standard karyotype and microarray are obtained 
from chorionic villi or amniocytes, or if specific pathogenic variants are known in the 
parents, targeted sequencing is performed. While microarray increases diagnostic yield 
above standard karyotype alone, 80–90% of anomalous fetuses with a normal karyotype also 
have a normal microarray and thus remain without a definitive diagnosis.2,3 Additional 
molecular genetic testing, either single gene or panels driven by phenotype may be 
performed if indicated and if a limited differential diagnosis suggests success for such 
targeted sequencing. Exome sequencing (ES), which provides sequence data from the exons 
(the coding regions) of known genes in the human genome, has proven to be a powerful 
diagnostic tool in adults and children with genetic disorders, such as birth defects and 
intellectual disability.4,5 Compared to a 10% diagnostic rate using karyotype with 
microarray, ES has diagnostic rates of approximately 30% in a post-natal cohort of patients 
with birth defects.4 The use of ES of fetal DNA obtained by amniocentesis has been reported 
in isolated cases.6,7 Small case series reporting increased diagnostic utility of ES prenatally 
after a normal microarray have also been published showing diagnostic rates ranging from 
10–57%.8–10 Thus, ES appears to be a promising technique to fill the existing diagnostic gap 
for fetal diagnosis.
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ES appears to be a promising technique because it has increased diagnostic capability when 
karyotype and microarray are normal and is less costly and more clinically applicable than 
whole genome sequencing. Our aim was to use ES to examine its utility for prenatal 
diagnosis in non-continuing (defined as pregnancy termination, intrauterine fetal demise, or 
neonatal death in the delivery room) pregnancies with multiple anomalies and normal results 
with standard prenatal genetic diagnostic tests (karyotype and microarray). Targeting this 
population for initial study focuses on those families with greatest need while avoiding some 
of the ethical complexities of communicating risk or study findings in on-going pregnancies. 
Additionally, because of the unique challenges related to implementation of exome 
sequencing prenatally, we sought to understand maternal perspectives, expectations, and 
understanding of fetal genetic results obtained by exome sequencing.
MATERIALS AND METHODS
Mother-father-fetus trios in pregnancies complicated by a fetus with multiple congenital 
anomalies were identified from the University of North Carolina at Chapel Hill prenatal 
diagnosis clinics (Chapel Hill, NC and Raleigh, NC) between July 2014 and July 2016. 
Approval from The University of North Carolina at Chapel Hill Institutional Review Board 
(13-4084) was obtained prior to patient consent and enrollment. Inclusion criteria include 
the following: 1) pattern of anomalies highly suggestive of an underlying genetic disorder; 
2) unknown diagnosis based on karyotype, microarray, and in some cases, gene specific 
sequencing; 3) Fetal and parental DNA available. Trios were identified prospectively and 
retrospectively, enabling us to obtain fetal specimens at various gestational ages. 
Prospectively, women pregnant with a singleton fetus suspected to have a lethal anomaly 
consistent with a genetic disorder were approached for participation after they made the 
decision to continue the pregnancy. In the case of non-continuing pregnancies, the research 
study was not mentioned or offered until after the couple had made a decision to terminate 
the pregnancy. Retrospective identification of potential trios was accomplished by querying 
the UNC Perinatal Database to identify women with a history of fetal or neonatal death who 
had not received an explanatory diagnosis by standard prenatal testing. We contacted women 
who previously indicated a desire to be re-contacted if additional fetal testing options 
become available and who had fetal cells archived and available for DNA extraction for 
potential enrollment. Additional participants in the retrospective cohort were either self-
referred or referred by a clinician aware of our current study recruitment. Once participants 
were enrolled, we collected parental blood and retrieved stored fetal samples for ES 
analysis. After the first 7 trios were enrolled, we expanded enrollment to individuals not 
receiving care at UNC; by using Skype to facilitate counseling, consent and results 
discussion in non-local cases. The sample size of 15 trios is a convenience sample for this 
pilot study.
Mothers and fathers from both retrospective and prospective groups had pretest counseling 
about ES and the possible results it can provide. Consent was obtained separately from 
mothers and fathers; both were informed about the possibility of ES revealing non-paternity. 
Participants were given the option to opt out at any time during the study. Because of the 
complexity of the genetic information that results from ES, consent and return of results 
were performed by a Certified Genetic Counselor who was not involved in the patient’s 
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clinical care to avoid bias and undue pressure on the patient to participate. All participants 
agreed to learn of 1) any diagnostic findings with potential to explain the fetal phenotype, 2) 
any medically actionable incidental findings in a parent that would have medically 
actionable implications for that parent,11 and 3) carrier status for significant autosomal 
recessive conditions in which both parents are carriers. Diagnostic results were classified 
into seven categories (Table 2). More than one result could be provided for a trio. After 
consent, we obtained parental blood and extracted DNA in the Biospecimen Processing 
Facility (BSP) or, for non-local cases, received DNA directly from an outside institution. If 
previously isolated DNA was not available, we extracted fetal DNA from stored products of 
conception, fetal amniocytes or villi (retrospective) or from umbilical cord blood, 
amniocytes, or chorionic villi (prospective). We split the DNA and sent a duplicate sample to 
the UNC Molecular Genetics Laboratory (MGL), a CLIA-certified and CAP-accredited 
facility, where it was stored and used for Sanger sequencing confirmation of genetic variants 
returned to participants. Duplicate samples streamline the process of variant confirmation 
and allow for quality checks between samples, as well as making results eligible for 
inclusion in the medical record. After confirmation with Sanger sequencing, parents were 
given the option to sign a separate consent form to have their own or their deceased child’s 
variants placed in the electronic medical record.
ES and Variant Analysis
We created ES libraries and exome capture from maternal, paternal, and fetal DNA samples 
as previously described12 and transferred them to the UNC High Throughput Sequencing 
Facility for sequencing using the Illumina Hi-Seq 2500. We processed, mapped, and aligned 
raw-read data, and identified variants using a standard bioinformatics pipeline developed for 
the NCGENES project in collaboration with colleagues in the Department of Genetics and 
the Renaissance Computing Institute.13
We captured quality metrics at all stages of processing to determine whether outputs could 
be used for analysis. Metrics include checks on input file correctness, distributions of 
nucleotide and quality scores, percent of reads aligned, read gap distributions, percent of 
reads with pairs, metrics on coverage across the genome and from targeted regions, and 
metrics from genome analysis toolkit (GATK) on called variants. Variants were annotated 
with information regarding predicted molecular effect (SnpEff)14 and population allele 
frequencies (ExAC).15 These additional annotations and trio data were used to filter and 
prioritize variants according to inheritance patterns (de novo, compound heterozygous 
variants, and homozygous recessive variants) within the trio using GEMINI.16 Similar to 
whole exome sequencing used post-natally, all protein coding regions of the genome were 
interrogated. We also used a “gene list prioritization” approach to present all known 
pathogenic, rare truncating, and rare missense variants in genes known to have an 
association with the fetal phenotype (examples of such gene lists are shown in 
Supplementary Tables). Gene lists specific to the phenotype in question were curated using 
the primary literature and by reviewing previously developed panels currently in use. When 
no finding was identified using a gene list, all homozygous variants and compound 
heterozygous variants in autosomal recessive disorders, and de novo variants in autosomal 
dominant disorder were manually reviewed. Variants were manually reviewed by molecular 
Vora et al. Page 4
Genet Med. Author manuscript; available in PMC 2017 November 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
analysts using multiple sources (e.g., mutation databases, Online Mendelian Inheritance of 
Man (OMIM), PubMed, Exome Aggregation Consortium (ExAC)) for potential function in 
relation to the phenotype.
A committee of clinical and laboratory geneticists, obstetricians, genetic counselors, and 
pediatricians who were not involved in the patient’s clinical care reviewed all findings of the 
molecular analysts to make a final determination about return to participants and result 
classification (e.g. positive-probable, uncertain VUS, etc.) using criteria developed by 
Richards et al. (Table 2).17. All variants thought to be potentially causative were reviewed by 
the committee within two weeks of the primary analyst identifying the variant. Results 
believed to clearly (or possibly) explain the fetal phenotype were reported to parents after 
confirmation in a CLIA-certified molecular genetics clinical laboratory. Also, all parental 
samples were analyzed for a small subset of “medically actionable” genes (e.g., BRCA1/2) 
per the American College of Medical Genetics and Genomics and any findings in the parents 
were reported.11,17–21 Parents also consented to return of carrier status for significant 
autosomal recessive conditions in which both parents are carriers. All reported variants, 
whether diagnostic or incidental, were confirmed by Sanger sequencing in a CLIA-certified 
molecular genetics laboratory. The diagnostic results were categorized into seven categories 
(Table 2).11,21,22
Assessment of Maternal Perspectives and Understanding
We completed a mixed-methods assessment using questionnaires and semi-structured 
interviews with 15 mothers. We focused on the mother’s perspectives and understanding in 
this pilot study. After informed consent, each mother completed a pre-sequencing 
questionnaire (8 questions related to demographics) and literacy genomic knowledge scale 
(25 true-false questions to assess recall and understanding of the structure and function of 
genes, how they are inherited, their relation to health, and strengths and limitations of ES). 
The literacy assessments were modified for prenatal use from previously used scales from 
the NCGENES project. A Wilcoxon rank sum test was performed to compare literacy 
genomic knowledge scores with income levels; a p-value less than or equal to 0.05 was 
defined as significant. This was followed by a semi-structured interview with the mother to 
identify expectations, understanding, and perceptions. To reduce bias, a trained research 
assistant rather than the genetic counselor or the PI, conducted the in-person interview with 
the mother (~45 minutes) adapted from a study of diagnostic genome sequencing in adult 
and pediatric patients (NCGENES; PI: Evans).
A trained research assistant conducted follow-up telephone post-quantitative and interview 
assessments with the mother 4 weeks after return of results to measure understanding and 
the impact of the information on future decisions.
RESULTS
Participant demographics of the cohort are shown in Table 1. Most (13/15) participants 
enrolled shortly after routine fetal genetic testing (CVS or amniocentesis for karyotype and 
microarray) was completed. All enrolled pregnancies had both normal karyotype and single 
nucleotide polymorphism (SNP) prenatal microarray. However, 2/15 were enrolled 5–10 
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years after the prior affected pregnancy (cases 1 and 2). Turn-around time to identify 
pathogenic variants once sequencing was performed ranged from 0 days to 28 days (mean 
21 days). Gene lists were developed and used for cases with skeletal findings, non-immune 
hydrops, and for genitourinary abnormalities. Two of the three skeletal cases were diagnosed 
using the skeletal dysplasia gene list prioritization approach (COL1A1 and DYNC2H1) and 
had the shortest turn around time (0 days to identify pathogenic variants once sequencing 
data was available).
Molecular Diagnoses
Genotype and phenotype data are listed in Table 4. In 7 (47%) of 15 trios, ES provided a 
diagnosis or possible diagnosis of the following disorders: osteogenesis imperfecta type 3 
(COL1A1), fetal akinesia sequence (MUSK), scalp-ear nipple syndrome (KCTD1), 
primordial microcephaly-dwarfism syndrome (RTTN); Meckel-Gruber syndrome 
(TMEM67); lymphatic dysplasia (PIEZO1); short rib polydactyly syndrome (DYNC2H1). 
Of the mutations found, there were two de novo mutations in the proband fetuses (COL1A1 
and KCTD1) and five autosomal recessive disorders (MUSK, RTTN, TMEM67, PIEZO1, 
DYNC2H1) conferring a 25% risk of recurrence in a subsequent pregnancy. ES provided 
evidence for expanding the phenotype in one of these syndromes (scalp-ear nipple 
syndrome; KCTD1) to the fetal period. There was a significant family history in only one 
fetal case (case 5; fourth pregnancy affected with arthrogryposis phenotype). Two cases 
(case 7 short rib polydactyly and case 9 meckel-gruber syndrome) had sufficient ultrasound 
findings to enable the provider to send the correct gene-specific panel for the specific 
phenotype of interest. Although other variants in our positive diagnoses could be detected by 
a gene panel (case 1 osteogenesis imperfecta), the ultrasound phenotype was not detailed 
enough (shortened long bones with bowing) for the provider to reliably pick the correct 
panel by the ultrasound findings alone. In addition, autopsy and skeletal survey findings can 
suggest the wrong diagnosis (case 1: autopsy and skeletal survey suggested 
hypophosphatasia when OI, type 3 was the diagnosis) which would have led the provider 
astray.
Demonstrating the potential of ES in fetuses to reveal new candidate genes for 
developmental disorders, in one case with complex cardiac defect and abnormal kidney 
location, a de novo stop gain mutation was found in MAP4K4. This gene is known to be 
integrally involved in vascular development and cell migration and is embryonic lethal in 
knockout mouse models but no human phenotype has yet been described.23 Because this 
gene has not been associated with human disease, the clinical significance of this variant is 
uncertain.
In two other cases, a single mutation in a gene associated with autosomal recessive 
inheritance of a phenotype consistent with the fetal presentation was identified. Incomplete 
sequencing coverage and the possibility of undetected deletions or duplications beyond what 
could be detected with microarray (all fetuses enrolled had normal microarrays) precluded 
exclusion of a second mutation.
We found only one medically actionable finding in a parent (familial hypercholesterolemia, 
LDLR); it was confirmed with Sanger sequencing. The parent in this case was already being 
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treated for high cholesterol and has a strong family history of hypercholesterolemia. The 
participant was encouraged to share the information with family members in the post-test 
counseling session. None of the couples had significant carrier results to report. Two couples 
chose to have fetalresults placed in the medical record. They plan to have prenatal diagnosis 
in a future pregnancy if the same anomalies are noted.
The mothers’ self-report of knowledge and attitudes revealed a median perceived likelihood 
of 5.2 on a 10 point likert scale (range=2–7) that ES would provide a result for the 
abnormalities identified in a couple’s fetus. Median genomic knowledge prior to sequencing 
was high (median 92; range 76–100). The study was not powered to detect a difference in 
genetics knowledge base assessment by socioeconomic background but there was a 
statistically significant finding that women in the highest socioeconomic group (>$90,000 
annually) had higher pre-sequencing genomic knowledge (median 95 (95% CI: 91.6–98.4) 
than their lower income counterparts (<$90,000 annually) (median 88 (95% CI: 85–92.6) 
[p<0.001]. Seventy five percent of the women who scored above the mean were in the 
highest income bracket. In the post-assessments, all of the women expressed understanding 
of their ES results and felt having ES was a good decision in the post-results surveys and 
interviews. In a qualitative interview, the parent who received the incidental finding felt 
having ES was beneficial to his long-term health.
DISCUSSION
Our series of non-continuing anomalous pregnancies shows that the diagnostic utility of ES 
after normal standard genetic testing yields a definitive or possible explanation in up to 
(7/15) 47% of cases where a fetal genetic diagnosis was highly suspected. This is on the 
higher end of prenatal yields reported by other authors of similarly small series which range 
from 10–57% and confirms that exome sequencing increases the diagnostic yield prenatally 
in a select group of anomalous fetuses who fail to receive a diagnosis with standard genetic 
testing.8–10,24 Criteria for study inclusion criteria, sample size, and diagnostic yield (DY) of 
other published studies are as follows: fetal demise or termination of pregnancy with 
multiple congenital anomalies with normal karyotype using trios (n=7) [DY=57%],10 
increased nuchal translucency (>3.5mm) and/or other abnormality with normal karyotype 
(n=24) [DY=21%],25diverse structural abnormalities on ultrasound using trios (n=30) 
[DY=10%].24 It is important to note that diagnostic yield of any test depends on the prior 
probability of detectable conditions within that cohort, so it is likely that our apparently 
higher yield and that of Alamillo et al. reflects the inclusion of fetuses with a higher 
likelihood of a genetic etiology given that both studies only included fetuses in non-
continuing pregnancies with multiple congenital anomalies. In addition, both our study and 
Alamillo et al. used trios consistently which improves diagnostic rates. The other studies 
with lower yields included fetuses with a single structural abnormality. The yield in a larger 
sample with broader inclusion criteria may be lower. In addition to selection of a cohort with 
a high likelihood of genetic etiologies, the interpretation of findings also influences 
diagnostic yield. Our approach was consistent with guidelines by Richards et al. and use of 
pre-established multidisciplinary variant analysis committees put in place for NCGENES 
(PI: Evans), thus, we do not feel our diagnostic yield was overinflated. Our study performed 
both karyotype and microarray on all included fetuses whereas other studies did not 
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consistently perform microarrays. Given that ES cannot detect larger copy number variants, 
we felt it important that chromosomal microarray be done prior to ES. Our findings suggest 
that ES will improve the accuracy of prenatal diagnosis in a select cohort of fetuses with 
multiple congenital abnormalities because ES has increased diagnostic capability when 
karyotype and microarray are normal.
Strengths of our study include the use of trios which enhances diagnostic yield and was not 
consistently used by other studies,8,26 development of fetal specific gene lists to optimize 
turn-around time, development and use of trio-specific bioinformatics pipelines, and use of a 
multidisciplinary genetics team to evaluate classification of all results reported with respect 
to pathogenicity of the variants and (for diagnostic results) the likelihood that those variants 
explained the phenotype.8,26 Our study also found that ES was useful in cases where a 
clinically available phenotype-driven panel did not provide an answer because we identified 
variants in genes that were not on the specific prenatal panel for the phenotype being tested, 
either because the gene had not been described at the time the panel was validated or 
because the phenotype was so heterogeneous that a complete panel could not be made 
(hydrops). Because we included only cases of non-continuing pregnancies, the postnatal 
exam of the fetus by a geneticist with autopsy was available in some cases to assist in 
refining the phenotype allowing us to specifically target genes associated with a particular 
phenotype and adding confidence when pathogenic variants were identified. Our study, 
along with previous studies, provides pilot data indicating that ES can improve prenatal 
diagnosis.
Given the important counseling issues inherent in ES, we also explored the important and 
critical issue regarding how mothers perceive and understand exome sequencing. Efforts to 
understand the psychosocial and behavioral impact of integrating genomic technologies into 
adult and pediatric practice are ongoing.27–29 To date, little empirical work has been done to 
understand the unique challenges of applying exome or genome sequencing to the prenatal 
context. The experience of prenatal diagnosticians and patients regarding response to 
variants of uncertain significance and incidental identification of maternal pathology after 
prenatal chromosomal microarray (CMA) has been studied, and raise a range of similar 
issues.30,31 These include complexities of trade-offs between better diagnostic ability than 
standard karyotype32 but also greater risk of results with uncertain clinical significance. 
While prenatal diagnosticians have incorporated pre- and post-test counseling into their 
practice to explain nuanced results, the issues are magnified by the use of ES in this 
population given the higher incidence of uncertain variants in a sequencing context.
We found that women with lower income levels scored significantly lower on the genetics 
literacy assessment compared to women in higher income levels. We also found that women 
had high hopes and expectations (Likert scale 5.4) that ES would provide a result despite 
pre-test counseling by a genetic counselor that ES has previously been shown to yield a 
result approximately 30% of the time. However, when using a Likert scale participants may 
choose the neutral option because picking a neutral option allows people to avoid the 
cognitive effort needed to choose between their positive and negative feelings on an issue.21 
Attitudes towards prenatal screening and diagnosis are influenced by ethnicity, 
socioeconomic status, cultural and religious beliefs, acceptability of termination of 
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pregnancy, and experiences with disability and further research on this critical topic is 
needed to ensure that patient’s needs are being met as new technologies inevitably become 
implemented in clinical practice.33–35
Our study also demonstrates how ES in this context can extend understanding of known and 
novel diseases that disrupt fetal development. The finding of a likely pathogenic variant in 
KCTD1 expands the phenotype of a known Mendelian disorder (scalp ear nipple syndrome) 
to the fetal period. The discovery of a de novo truncating mutation in MAP4K4 in a fetus 
with a complex heart defect makes this gene a novel candidate gene for a human 
developmental disorder given this gene’s critical role in embryonic development of the heart 
in mouse models.23,36,37 Further supporting the possibility of this gene as causative of the 
described phenotype is its de novo status. Further in vivo studies are planned using a 
zebrafish model to explore this intriguing finding.
Limitations of our study include relatively small sample size and selection of cases with a 
high a priori likelihood of having a genetic etiology. As cost decreases, ES may be more 
cost-effective than pursuing multi-gene panels, although analytic considerations, such as 
depth of coverage and coverage across exons may be optimal with molecular panels. Our 
study was not powered to identify statistical differences in outcomes related to maternal 
expectations and understanding; this is an area that needs further exploration in larger 
clinical studies of prenatal ES especially given that trends from this study show lower 
knowledge scores related to socio-economic status.
While ES is a promising diagnostic technology in the prenatal, childhood, and adult settings, 
there remain important limitations and ethical issues with the use of this technology, 
including provision of adequate counseling and informed consent. False negatives should be 
expected with ES given that most platforms cover only 85–90% of exons. Turn-around time 
has been cited as an issue when ES is applied prenatally but use of phenotype specific gene 
lists and trio analysis, as in the current study, has substantially decreased turn-around time.38 
Certainly, before ES is routinely implemented prenatally, turn-around time needs to be 
optimized so that reproductive decisions can be made in a timely manner. There are also 
ethical issues related to trio-sequencing including disclosure of identifying non-paternity, 
consanguinity, and medically actionable findings parents. In addition, if ES is applied in 
ongoing pregnancies, the additional ethical issue of being able to report a predisposition to 
adult onset disorders from fetal information arises. These issues will require ongoing ethical 
consideration as well as access to comprehensive genetic counseling by a certified genetic 
counselor with prenatal experience.
The results of the current study show that ES provides information to families, expands 
clinical phenotypes to the fetal period, and will likely enhance our knowledge of genes 
critical to fetal development. Neither the ACMGG nor the American College of Obstetrics 
and Gynecology recommends that ES be used routinely.20,39 Questions about the most cost-
effective and efficient way of identifying pathogenic variants in fetuses that do not receive a 
result with CMA should be addressed in larger clinical trials. Given the importance of 
responsibly applying new technologies to the broadest population possible, including 
traditionally underserved patients, decision aids in conjunction with a genetic counseling 
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session should be developed and studied to determine whether these interventions improve 
understanding of the types of results ES may provide. Further studies on both diagnostic 
utility and maternal expectations and understanding of prenatal ES are crucial before this 
technology becomes routinely incorporated into prenatal care.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Demographics of the mothers
Characteristics Study Cohort (n=15)
Age (years)
 Mean (SD [range]) 32.0 ± 5.11(22–39)
Race
 Caucasian White 14 (93.3%)
 African American 1 (6.6%)
Education Level
 High school graduate or equivalent 1 (6.6%)
 College education 11 (73.3%)
 Graduate or professional degree 3 (20.0%)
Total family income
 44,999 or less 4 (26.6)%
 45,000–89,999 5 (33.3%)
 90,000 or higher 6 (40%)
Prior genetic testing to look for causes of health problems
 Yes 8 (53.3%)
 No 7 (46.6%)
Married
 Yes 13 (86.7%)
 No 2 (13.3%)
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Table 2
Classification scheme of case-level results10,18,20,21
Positive
Positive-Definitive Known pathogenic variant(s) in a known disease gene and consistent with inheritance pattern; fetal phenotype 
consistent with the reported disease spectrum
Positive-Probable Likely pathogenic variant(s) in a known disease gene and consistent with the inheritance pattern; fetal phenotype 
consistent with the reported disease spectrum
Positive-Possible A single rare or novel VUS known to be in trans with a pathogenic/known pathogenic variant in a gene that explains 
the phenotype
Uncertain
Uncertain-VUS Variant(s) of uncertain significance in a known disease gene and consistent with the inheritance pattern; fetal 
phenotype consistent with the reported disease spectrum. (e.g. uncertainty is limited to the pathogenicity of the 
variant).
Uncertain-AR Het Single heterozygous variant (known pathogenic, likely pathogenic, or highly suspicious variant of uncertain 
significance) identified in a disease gene implicated in a recessive condition; fetal phenotype consistent with the 
reported disease spectrum
Uncertain-Contributory Known pathogenic or likely pathogenic variant(s) in a known disease gene, but fetal phenotype is not completely 
consistent with the reported disease spectrum and thus the finding may contribute to but not completely explain the 
phenotype
Uncertain-Other Category of other findings having uncertain case-level significance, including potential novel gene discoveries. For 
example, predicted deleterious variant(s) in a novel candidate gene that has not previously been implicated in human 
disease or for which the published data to support human disease association may not yet be definitive. Supporting 
data could be based on model organism data, CNV data, tolerance of the gene to sequence variation, data about tissue 
or developmental timing of expression, or knowledge of the gene function and pathway analysis. Further research is 
required to evaluate any of the suggested candidate genes.
Negative
Negative No variants in genes associated with the reported phenotype identified.
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